Related Experiment Videos
[Respiratory syncytial virus infections and preventive options]
P H Rothbarth1, J L Kimpen, J J Roord
1Laboratorium Microbiologie Twente Achterhoek, Enschede.
Nederlands Tijdschrift Voor Geneeskunde
|February 9, 2000
Summary
Respiratory syncytial virus (RSV) causes severe respiratory infections in young children. Palivizumab, a monoclonal antibody, significantly reduces hospitalizations in high-risk infants, offering crucial prevention for serious RSV disease.
Area of Science:
- Pediatrics
- Infectious Diseases
- Immunology
Context:
- Respiratory syncytial virus (RSV) is a leading cause of pediatric respiratory infections, particularly bronchiolitis in infants.
- Approximately 2000 children in the Netherlands require hospitalization annually due to RSV.
- High-risk infants, including premature infants and those with congenital conditions, face severe RSV outcomes.
Purpose:
- To evaluate the efficacy of palivizumab for preventing serious respiratory syncytial virus (RSV) disease in high-risk children.
- To inform clinical practice regarding the use of palivizumab for RSV prevention in vulnerable pediatric populations.
Summary:
- Palivizumab, a monoclonal antibody, is administered monthly for five months during the RSV season.
- Clinical studies demonstrate that palivizumab significantly reduces RSV-related hospital admissions and hospital stay duration in high-risk children.
- Treatment is symptomatic for most RSV cases, with antivirals reserved for immunocompromised patients.
Impact:
- Palivizumab provides a vital preventive measure against severe RSV infections in at-risk infants.
- The use of palivizumab can decrease the burden on healthcare systems by reducing pediatric hospitalizations.
- This passive immunization strategy improves outcomes for infants susceptible to serious respiratory syncytial virus disease.